On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%. JNJ reported a net profit of $5.35 billion compared to a net loss of $(491) million a year ago, which included litigation charges of $6.9 billion. Innovative Medicine segment worldwide operational sales, excluding the COVID-19 Vaccine, ...